Navigation Links
Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Society's 57th Annual Meeting
Date:1/13/2011

tly less opioids were consumed over the first 24 hours after surgery in the EXPAREL group (p=0.0077);
  • EXPAREL was well tolerated in patients who received postsurgical treatment for pain following bunionectomy; 59.8% of patients treated with EXPAREL experienced an adverse event compared to 67.7% of patients treated with placebo;
  • Most of the adverse events were not considered related to study drug and were mild or moderate in severity.

  • The full poster can be found on the Pacira website at www.pacira.com.  

    In December 2010, Pacira announced that its New Drug Application (NDA) for EXPAREL had been accepted for filing by the U.S. Food and Drug Administration (FDA). Pacira submitted the EXPAREL NDA in September 2010 for the initial indication of postsurgical analgesia by local administration. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of July 28, 2011 for the review of the EXPAREL NDA.

    About EXPAREL™EXPAREL is Pacira's proprietary drug candidate consisting of bupivacaine encapsulated in DepoFoam®, both of which are currently used separately in FDA-approved products. Bupivacaine is a well-characterized anesthetic/analgesic that has an established safety profile with more than 20 years of use in the United States. Several Phase 2 and Phase 3 clinical trials have been completed for EXPAREL and demonstrate statistically significant reduction of pain in soft tissue and orthopedic surgery in different surgical models. Clinical data has also demonstrated that EXPAREL provides analgesia for up to 72 hours post-surgery compared with 7 hours or less for bupivacaine. The safety of EXPAREL was evaluated in 10 randomized, double-blind, local administration into the surgical wound clinical studies involving 823 patients; the most common adverse events following EXPAREL administration were nausea, constipation, and vomiting.  

    About PaciraPacira P
    '/>"/>

    SOURCE Pacira Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
    2. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
    3. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
    4. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
    5. Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile
    6. Reportlinker Adds OTC Pharmaceuticals: Global Industry Almanac
    7. ADVENTRX Pharmaceuticals Announces Closing of $22.5 Million Financing
    8. Anadys Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
    9. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
    10. Topaz Pharmaceuticals Names Dr. Mark Strobeck Chief Business Officer
    11. Optimer Pharmaceuticals Announces Key Additions to Management Team
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... Va. , Aug. 27, 2015  The ... the Food and Drug Administration,s (FDA,s) draft guidance ... reference products and biosimilars, to bear a nonproprietary ... AMCP has been seeking a decision from the ... 18 diverse health care stakeholders urging the agency ...
    (Date:8/27/2015)... Biosimilars are not generics and the ... and Drug Administration (FDA) for recognizing that each ... guidance issued today. The FDA,s draft guidance on ... calling for biological products to bear a nonproprietary ... reflects the agency,s thinking that "there is a ...
    (Date:8/27/2015)... INDIANAPOLIS , Aug. 27, 2015  Eli Lilly ... Morgan Stanley Global Healthcare Conference on Thursday, September 17, ... and president of Lilly Oncology and Richard Gaynor ... medical affairs for Lilly Oncology, will participate in a ... A live audio webcast will be available ...
    Breaking Medicine Technology:AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Lilly to Participate in Morgan Stanley Global Healthcare Conference 2
    ... , VIENNA, Va., Jan. 11 CEL-SCI Corporation ... a developer of vaccines and therapeutics for the prevention and ... validation of all critical utilities and manufacturing equipment at its ... represents a very important milestone as it allows CEL-SCI to ...
    ... SANTA MONICA, Calif., Jan. 11 Derycz Scientific (OTC Bulletin Board: ... the flow of information from content publishers to enterprise customers and ... 2010, on the website of DDN ( Drug Discovery ... Peter Derycz, is titled "Speeding the Path to FDA Approval in ...
    Cached Medicine Technology:CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 2CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 3CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 4Derycz Scientific Featured In DDN (Drug Discovery News) 2Derycz Scientific Featured In DDN (Drug Discovery News) 3
    (Date:8/28/2015)... ... August 28, 2015 , ... Drugs ... Dr. James Strawbridge, gives a new approach on solutions in his new book ... the employer and employees getting together for meaningful group meetings. "This would educate ...
    (Date:8/28/2015)... ... August 28, 2015 , ... The Nashville Business Journal recently ... in business. Mr. Troy Mizell, Chairman of the Board at MyGenetx, is ... 2015 Veterans Awards will recognize Nashville military veterans who, through their professional and ...
    (Date:8/28/2015)... ... ... Gregory K. Toumayan, D.C., Q.M.E., is now treating patients with back pain and associated ... pain, stiffness, muscle spasms, and numbness. , Dr. Toumayan received his Bachelor of ... earn his title of Doctor of Chiropractic from the Palmer College of Chiropractic and ...
    (Date:8/28/2015)... ... ... The Quatela Center for Plastic Surgery is excited to bring patients the ... by the Food and Drug Administration to eliminate submental fat, also known as the ... are among the premier cosmetic surgeons in Rochester to offer this innovative procedure.     , ...
    (Date:8/28/2015)... , ... August 28, 2015 , ... Mendon, IL, home ... good music and good people, all for a good cause. In its second year, ... sponsored once more by Best Drug Rehabilitation. The “Mission” of “Music With A Mission” ...
    Breaking Medicine News(10 mins):Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2
    ... Feb. 8 (HealthDay News) --The U.S. Food and Drug Administration ... safe during some MRI scans. Pacemakers are medical devices ... beats. Until now, patients with pacemakers who needed an MRI ... used by the MRI could disturb the pacemakers, settings or ...
    ... , TUESDAY, Feb. 8 (HealthDay News) -- Heavy ... adulthood and is associated with long-term alcohol-related problems, researchers ... reducing drinking among older teens not only prevents immediate ... problems, the study authors pointed out. The researchers ...
    ... at the University at Buffalo have devised two new ... important molecules from losing their shape and degrading in ... the development of peptide-based drugs against diseases including cancer. ... than existing techniques, one of which employs an expensive ...
    ... (HealthDay News) -- Babies who are exposed to HIV at ... levels of antibodies to diseases such as whooping cough, tetanus ... samples from 104 HIV-infected and uninfected South African women and ... of the infants at 16 weeks of age. The samples ...
    ... (HealthDay News) -- Repeat cases of shingles may be more ... long-held belief that people only get shingles once in a ... rash and sometimes severe pain. The condition is caused by ... Center in Rochester, Minn., analyzed the medical records of nearly ...
    ... Ariz., Feb. 8, 2011 The Muscular Dystrophy Association ... new research to advance understanding of disease processes and ... and other related neuromuscular diseases affecting more than a ... possible by generous public support of the MDA Labor ...
    Cached Medicine News:Health News:FDA Approves First Pacemaker Deemed Safe During MRIs 2Health News:New techniques for stapling peptides could spur development of drugs for cancer 2Health News:Mom's HIV May Lower Baby's Immunity to Other Diseases 2Health News:Shingles Returns More Often Than Thought 2Health News:MDA awards $13.5 million in grants for research treatments for neuromuscular diseases 2Health News:MDA awards $13.5 million in grants for research treatments for neuromuscular diseases 3Health News:MDA awards $13.5 million in grants for research treatments for neuromuscular diseases 4
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: